Chemotherapy for Advanced Lung Cancer: A Study
Author Information
Author(s): R.L. Woods, C.J. Williams, J. Levi, J. Page, D. Bell, M. Byrne, Z.L. Kerestes
Primary Institution: Royal North Shore Hospital
Hypothesis
Does chemotherapy improve survival in patients with advanced non-small cell lung cancer compared to supportive care only?
Conclusion
Chemotherapy did not significantly improve survival compared to no chemotherapy in patients with advanced non-small cell lung cancer.
Supporting Evidence
- The overall response rate to chemotherapy was 28%.
- Median survival for the chemotherapy group was 27 weeks, compared to 17 weeks for the control group.
- Toxicity was severe, with many patients discontinuing treatment due to side effects.
Takeaway
Doctors wanted to see if a special medicine could help people with a serious lung problem live longer, but it didn't really help them much.
Methodology
Patients were randomly assigned to receive either chemotherapy or no chemotherapy, and their survival and response to treatment were evaluated.
Potential Biases
Patients with better prognostic criteria may have been overrepresented.
Limitations
The study did not effectively measure quality of life, and the chemotherapy caused severe toxicity in many patients.
Participant Demographics
Median age was 61 years, 82% were men, and most had an ECOG performance status of 0 or 1.
Statistical Information
P-Value
0.33
Statistical Significance
p=0.33
Want to read the original?
Access the complete publication on the publisher's website